SARomics Biostructures' news archive

Press release

SARomics Biostructures, Red Glead Discovery and researchers at Sahlgrenska Cancer Center jointly collaborate in this project that was one of 15 financed by Swelife in order to increase health and well- being as well as increasing the sustainable growth and competitiveness of Swedish life science. In the project, a preclinical innovative epigenetic therapy will be significantly advanced towards clinical studies for an orphan cancer indication. Press release…

Aqilion AB contracts integrated drug discovery project with SARomics Biostructures and Red Glead Discovery. The aim of the project is to develop drug candidates that bind to a target protein that is essential for both malignant disease development and for inflammatory conditions. A successful project can therefore help to develop new medications to treat orphan drug indications in the field of autoinflammatory diseases, as well as new combination therapies within the field of oncology, primarily intestinal cancer. Read more…

SARomics Biostructures will assist Follicum AB to study FOL peptide binding to receptors on pancreatic cells. The new research will broaden the knowledge base within the company's project aimed at the development of a peptide-based treatment for diabetes. The project will study FOL peptide binding to the surface receptors / targets previously identified on pancreatic cells to investigate how this binding results in an increase in insulin secretion at the same time as the pancreatic cells are protected and preserved.. Read more…

SARomics Biostructures and Red Glead Discovery acquire the weak-affinity chromatography (WAC™) technology from Transientic Interactions AB. Press release… (in Swedish)

SARomics Biostructures will use its 3D structure determination capabilities to assist Alligator Bioscience AB, a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, to verify the unique functionality of ATOR-1017, an immuno-stimulatory antibody in development for the treatment of metastatic cancer. Read more…

University of Copenhagen, SARomics Biostructures and Enamine join forces to develop the next generation of safer anti-depressants in an EU-funded project Selective Agonists For Serotonin Receptors (SAFER). Read more… or visit project site SAFER

SARomics Biostructures & Carna Biosciences sign exclusive distribution agreement covering the Japanese market,
Press release…

SARomics Biostructures opens U.S. sales office!
Press release…

SARomics Biostructures and Xbrane Bioscience form a strategic partnership for “off-the-shelf” protein structures,
Press release...

SARomics Biostructures and
BioVersys join efforts to combat multidrug-resistant bacterial infections, Press release...

SARomics Biostructures first Nordic company to obtain growth capital through a collaborative initiative between Sparbanken Öresund and the European Investment Fund,
Press release

SARomics Biostructures coordinates an EU-funded industry-academia drug discovery partnership,
Press release...

SARomics Biostructures and Red Glead Discovery enter lead discovery collaboration in the field of epigenetic disorders,
Press release...

SARomics Biostructures brings in new strategic owners,
Press release...

SARomics Biostructures coordinates KINOMED, Eurostars funded kinase project,
Press release...

Inimex Pharmaceuticals and SARomics Biostructures Announce Successful Achievement of Key Scientific Milestone in Structural Biology Collaboration.
Press release...

UNIZYME Laboratories and SARomics enter into drug discovery collaboration
press release

SARomics and Alligator Bioscience, Lund, have entered into a collaboration agreement. Press Release
Other news

SARomics Biostructures announces the adaptation of a new graphics profile with a new company logotype and introduces Protein Shop - a catalogue of recombinant proteins for scientific research.

7 new structures added to the Premium FastLane™ list of off-the-shelf structures:
STK10 kinase - LOK or Serine/threonine-protein kinase 10
EphA7 kinase - Ephrin type-A receptor 7
GMPR2 - GMP reductase 2
LSD1 - KDM1A or Lysine-specific histone demethylase 1A
ROR-gamma - Nuclear receptor ROR-gamma
Tubulin - Pig tubulin alpha-1A
CLK3 - Dual specificity protein kinase CLK3

SARomics Biostructures and Red Glead Discovery introduce their new unique and exclusive high-throughput fragment screening service using WAC™ (
weak affinity chromatography) at the FBLD2016 conference in Cambridge, MA.

SARomics Biostructures together with Novo Nodisk and MAXIV laboratory arrange the 24th Protein Structure Determination in Industry meeting, PSDI, which will take place 13-15 November 2016 in Malmö, Sweden.


SARomics Biostructures collaborates with Prof. G Schneider (ETH Zürich) in a study in which automated molecular de novo design led to the discovery of an innovative inhibitor of death-associated protein kinase 3 (DAPK3)!
Read more…

EU funded & SARomic Biostructures coordinated kinase drug discovery project TAKTIC featured in the US based
Drug Discovery News

SARomics Biostructures is featured in
MedChemWatch, the official Newsletter of the European Federation for Medicinal Chemistry (EFMC)

SARomics Biostructures moves together with Lund Life Science Incubator to a new location at the
Medicon Village.

The article on the industrially important omega-transaminase structures determined by SARomics Biostructures has been selected for the latest Virtual Issue of FEBS Journal. The work was done in collaboration with researchers at the Royal Institute of Technology (KTH) in Stockholm and AstraZeneca in Södertälje has been selected for the latest Virtual Issue of FEBS Journal, which showcases the best contributions published in the past year by the journal in the field of molecular enzymology. This accolade confirms SARomics Biostructures strength in the field of industrial enzymology.
Link to the article...

SARomics Biostructures has determined an additional crystal structure of the carbohydrate recognition domain of galectin-3 in complex with a designed ligand. The ligand was developed by a research group headed by Professor Ulf Nilsson and Professor Hakon Leffler at the Depts. of Organic Chemistry and Division of Microbiology, Immunology and Glycobiology at Lund University, respectively. Prof. Nilsson and Prof. Leffler have recently co-funded the company
Galecto Biotech which focuses on developing novel drugs targeting galectins for the treatment of fibrosis, inflammation and other serious human diseases.

ProPHECY™ technology successfully used in the design of potent antimicrobial peptides. Press release...

SARomics Biostructures enters collaboration agreement with MAX IV synchrotron facility in Lund.